Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

380 participants · First posted Mar 19, 2025

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

135 participants · First posted Jul 25, 2022

Lorcaserin

C₁₁H₁₄ClN

Trazodone(Desyrel, Oleptro)

C₁₉H₂₂ClN₅O · Rx

Anti-CEA-HERA-CD40L(Apogenix)

Epygenix Therapeutics, Inc.

United States

Apogenix AG

Germany

Apogenix GmbH

Germany

Harmony Biosciences to Present Phase 3 EPX-100 Data for Dravet Syndrome at AES Annual Meeting

Xenon Pharmaceuticals Appoints Darren Cline as Chief Commercial Officer Ahead of Azetukalner Phase 3 Data

Epilepsy Drug Pipeline Shows Robust Growth with 90+ Therapies in Development Across 75+ Companies